{"id":58256,"date":"2024-08-13T12:04:00","date_gmt":"2024-08-13T12:04:00","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/08\/13\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/"},"modified":"2024-08-13T12:04:00","modified_gmt":"2024-08-13T12:04:00","slug":"evoke-pharma-inc-reports-second-quarter-2024-financial-results","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/","title":{"rendered":"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results"},"content":{"rendered":"<div>\n<p align=\"center\"><strong><em>GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million<\/em><\/strong><\/p>\n<p align=\"center\"><strong><em>Achieved record-high prescription fills during Q2<\/em><\/strong><\/p>\n<p align=\"center\"><strong><em>75% year-over-year prescription fill increase; 32% growth compared to Q1 2024<\/em><\/strong><\/p>\n<p align=\"center\"><strong><em>Two abstracts submitted and accepted by the American College of Gastroenterology (ACG) focusing on use of GIMOTI in patients on GLP-1 analogs<\/em><\/strong><\/p>\n<p align=\"justify\">SOLANA BEACH, Calif., Aug.  13, 2024  (GLOBE NEWSWIRE) &#8212; Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI<sup>\u00ae<\/sup>\u00a0(metoclopramide) nasal spray,\u00a0today announced its financial results for the second quarter ended June 30, 2024, and recent corporate developments.<\/p>\n<p align=\"justify\">Matt D\u2019Onofrio, CEO of Evoke Pharma, commented, &#8220;Exiting the second quarter of 2024 with nearly 50% growth in revenue from the previous quarter is a testament to the effectiveness of our commercial strategy. This quarter, we made history by hitting record-high prescription fills while witnessing increases in all other key sales metrics.&#8221;<\/p>\n<p align=\"justify\">\u201cWe are continuing to see growth in all phases of our business with increases in HCPs prescribing, patients taking GIMOTI, improvements in covered prescriptions with each showing our best performance in quarter over quarter growth in Q2. As of June 30, 2024, GIMOTI has over 2,000 cumulative prescribers. Additionally, our partnership with ASPN Pharmacies continues to yield strong results, notably in the conversion of prescriptions to fills,\u201d Mr. D\u2019Onofrio added.<\/p>\n<p align=\"justify\">Chris Quesenberry, Chief Commercial Officer for GIMOTI, stated, \u201cEversana\u2019s aligned goal with Evoke is to improve the lives of patients suffering from diabetic gastroparesis by improving access to GIMOTI and offering it as in important alternative to current oral options. Sixty-five percent of patients are dissatisfied with current therapies for their gastroparesis, which is unacceptable. We will continue to challenge the narrative that \u201cpatients are doing fine,\u201d taking our message to providers and patients alike. Our strategies to grow our prescriber and patient base are working, as the GIMOTI clinical data and their personal experience on treatment is resonating with patients and providers. Our current and planned strategic initiatives are poised to support continued momentum as we have only scratched the surface of the total opportunity thus far.\u201d<\/p>\n<p><strong>Second Quarter 2024 Developments and Recent Highlights:<\/strong><\/p>\n<p><strong>Strong Commercial Progress with GIMOTI <\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt; text-align:justify;\">Achieved positive momentum with transition to ASPN Pharmacies\u2019 comprehensive servicing platform.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">Expanded access by increasing our filling pharmacy network with four additional pharmacies in prioritized states and sales territories.<\/li>\n<\/ul>\n<p align=\"justify\"><strong>Unveiled Further Benefits of GIMOTI at Medical Meetings and Webinars <\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt; text-align:justify;\">Presented data at the 2024 Digestive Disease Week (DDW) in May, demonstrating a significant reduction in physician office visits, inpatient hospitalizations, and emergency department visits in women who had diabetic gastroparesis compared to those taking oral metoclopramide.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">Held virtual webinar in April featuring Michael Cline, DO., Medical Director Gastroparesis Clinic at the Cleveland Clinic in April to discuss compelling healthcare resource utilization data showing improved hospitalization rates, and his view on patient experience with GIMOTI. <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VsY87ygmXLvSbPgxpgw-YI3WElZ5uhR7B3IU8y9zHqgc6aNdYLyp61xVLgdpfK_QuwppyNiNtLWM6KTux5JS0KzS3O_vsOQDZLGfy6TaItRUbqFWhMufVOsRyUCceEVPZjr73OvA8lx-z0Jv6NIViImYtfU8ZzOwMjPfIQ1ijfFUD0CgY6jd7smGSFzzDvU7ykdzajggm6lh7djHAUh6jRPec-fmAKmJyuEMfG39vvI=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Video link here\">Video link here<\/a>.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">Two abstracts submitted and accepted by the American College of Gastroenterology (ACG) focusing on use of GIMOTI in patients on GLP-1 analogs.<\/li>\n<\/ul>\n<p><strong>Leadership Appointments<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt;\">Promoted former COO, Matt D\u2019Onofrio, to Chief Executive Officer.<\/li>\n<li style=\"margin-top:6pt;\">Promoted former VP of Finance, Mark Kowieski, to Chief Financial Officer.<\/li>\n<\/ul>\n<p><strong>Implemented Reverse Stock Split <\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt; text-align:justify;\">Evoke Pharma Board of Directors approved a 1-for-12 reverse stock split of the company\u2019s common stock, which began trading on a split-adjusted basis on August 1, 2024.<\/li>\n<\/ul>\n<p align=\"justify\">&#8220;Our commitment remains steadfast in amplifying and emphasizing the benefits and practical applications of GIMOTI to reach as many patients as possible and grow revenues, thus doing well by doing good. We continue to receive inbound questions from physicians regarding diabetic gastroparesis and patients on GLP-1 analogs and have submitted two abstracts to ACG in response. We remain energized by the encouraging results generated to date and look forward to building on this momentum throughout the rest of the year,\u201d Mr. D\u2019Onofrio concluded.<\/p>\n<p align=\"justify\"><strong>Second Quarter 2024 Financial Review and Outlook<\/strong><\/p>\n<p align=\"justify\">For the second quarter of 2024, net product sales were approximately $2.6 million compared to $1.1 million during the second quarter of 2023, and the net loss was approximately $1.3 million, or $0.93 per share compared with $1.9 million, or $6.70 per share, for the second quarter of 2023.<\/p>\n<p align=\"justify\">For the second quarter of 2024, selling, general and administrative expenses were approximately\u00a0$3.7 million\u00a0compared to\u00a0$2.8 million\u00a0for the second quarter of 2023. The increases were due to higher professional fees and reimbursement for expanded marketing efforts and profit-sharing activity with EVERSANA.<\/p>\n<p align=\"justify\">Total operating expenses for the second quarter of 2024 were approximately\u00a0$3.8 million\u00a0compared to\u00a0$2.9 million\u00a0for the same period in 2023.<\/p>\n<p align=\"justify\">As of June 30, 2024, cash and cash equivalents were approximately $9.2 million. We believe, based on our current operating plan, that our existing cash and cash equivalents, as well as future cash flows from net product sales of GIMOTI, will be sufficient to fund our operations into the second quarter of 2025.\u00a0<\/p>\n<p align=\"justify\">Based on net sales generated in the first two quarters of 2024, Evoke is revising its 2024 guidance to a range of $11- 12 million from $14 million, still reflecting over a 100% increase from the previous year if achieved. Evoke\u2019s 2024 guidance is dependent on its current business and expectations, including recent growth rates in net sales, assumptions regarding reimbursements and prescription fills, as well as factors that are outside of our control, such as the global macroeconomic and geopolitical environment, continued supply chain constraints and inflationary pressures.<\/p>\n<p align=\"justify\"><strong>About Evoke Pharma,Inc.<\/strong><\/p>\n<p align=\"justify\">Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.<\/p>\n<p align=\"justify\">Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.<\/p>\n<p>Visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=THQ9_ZLrwHLyEeJFPVmUr9RD46oBCODYze3hEa6HzAsePJY8aNsfoci224VOxMzXPBCk8nq5bIyrgzHyV-5X3ux0mvuFAiaF0ADGKdjOIq8=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.EvokePharma.com\">www.EvokePharma.com<\/a>\u00a0for more information.<br \/>Follow GIMOTI on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MXdPh38AnFFVUS83NSH_aGndHFQZq5L1jgxUUZy97oANO2gsfgsklqoQ9GteAfneKZtB92tOIEYtUULWy_KZ6d6E3jL2cP2G26ye82WHM12HY390nseRcTT6sRkzd0IL\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Facebook\">Facebook<\/a><br \/>Follow\u00a0Evoke Pharma\u00a0on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MVXtoAe_jmGJ8h_mqWtHtmHJbyVPrARpnyj-2cwRdFwG7IPSsIklVeCZh46GRNSgGUb2aP-FWXA2uM9J9Zd39GVosS4zumGwI-q_etChlYo9BR-SwCfyU43L3ObIolwkykEEC6wLBFKRMDC4xzDj_g==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"LinkedIn\">LinkedIn<\/a><br \/>Follow\u00a0Evoke Pharma\u00a0on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=y4OUgUXMLgY-isBKYT1nMz7d0A5inaFyhtHt4Dlpk8YqhSRpp7ORvb-GluqtdwWV-NFAKadeT6vHUcIiodG3DA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Twitter\">Twitter<\/a><\/p>\n<p><strong>About Gimoti<\/strong><sup><strong>\u00ae<\/strong><\/sup><strong> (metoclopramide) nasal spray<\/strong><\/p>\n<p>GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information<\/p>\n<p>WARNING: TARDIVE DYSKINESIA<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt; text-align:justify;\">Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use<em>.<\/em><\/li>\n<\/ul>\n<p>GIMOTI is not recommended for use in:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt; text-align:justify;\">Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates<em>.<\/em><\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL\/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.<\/li>\n<\/ul>\n<p>GIMOTI is contraindicated:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:6pt; text-align:justify;\">In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive\/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.<\/li>\n<li style=\"margin-top:6pt; text-align:justify;\">In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.<\/li>\n<\/ul>\n<p align=\"justify\">Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (\u22655%) for GIMOTI are: dysgeusia, headache, and fatigue. These are not all of the possible side effects of GIMOTI. Call your doctor for medical advice about whether you should take GIMOTI and the possible risk factors and side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.<\/p>\n<p>Visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xU7jd3c19SCi5Idi_274VgGFw9Q0K4HGz3aayj9s3WffLuSyYX4jQT7LLabcRLC-XQxQ_1njkaFOXbHS3c-bEKSfMHCYfWm6tTQ939lqYFo=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"www.fda.gov\/medwatch\">www.fda.gov\/medwatch<\/a>\u00a0or call 1-800-FDA-1088.<\/p>\n<p><strong>Safe Harbor Statement<\/strong><\/p>\n<p align=\"justify\">Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201dexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential\u201d or \u201ccontinue\u201d or the negatives of these terms or other similar expressions. These statements are based on the company\u2019s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke\u2019s or EVERSANA\u2019s marketing efforts; Evoke\u2019s commercialization plans, the potential market opportunity for GIMOTI, Evoke\u2019s partnership with ASPN Pharmacies, growth in prescriptions, patients taking GIMOTI and the conversion of prescriptions to fills, and Evoke\u2019s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke\u2019s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke\u2019s and EVERSANA\u2019s ability to successfully drive market demand for GIMOTI; Evoke\u2019s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke\u2019s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke\u2019s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke\u2019s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.<\/p>\n<p><strong>Investor &amp; Media Contact:<\/strong><br \/>Daniel Kontoh-Boateng <br \/>DKB Partners<br \/>Tel: 862-213-1398<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pma6ieCylYjumqQ0QFNa2-F23NS8U0qcjQJrKo6EFaTfAx0OVmvPrQ0tKZNLXs09KUn24psHXv83sbleDCwDxkz50_lDoW7LrIxBmptmasM=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"dboateng@dkbpartners.net\">dboateng@dkbpartners.net<\/a><\/p>\n<p align=\"center\"><\/p>\n<table align=\"center\" style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>Evoke Pharma, Inc.<\/strong><br \/><strong>Condensed Balance Sheets<\/p>\n<p><\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \"><strong>June 30, 2024<\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \"><strong>December 31, 2023<\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \"><strong>(unaudited)<\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>Assets<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Current assets:<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:66%; width:66%; min-width:66%;;vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Cash and cash equivalents<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:14%; width:14%; min-width:14%;;text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">9,177,836<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:14%; width:14%; min-width:14%;;text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">4,739,426<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accounts receivable, net of allowance for credit losses of $0<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">2,003,003<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">673,071<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Prepaid expenses<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">382,936<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">885,040<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Inventories<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">544,765<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">481,840<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Other current assets<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">27,675<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">47,532<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total current assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">12,136,215<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">6,826,909<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Deferred offering costs<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">241,637<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total assets<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">12,136,215<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">7,068,546<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \"><strong>Liabilities and stockholders&#8217; equity (deficit)<\/strong><\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Current liabilities:<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accounts payable and accrued expenses<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">2,183,850<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">1,711,778<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accrued compensation<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">425,797<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">1,324,010<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Note payable<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">5,000,000<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">5,000,000<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accrued interest payable<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">1,861,610<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">1,612,295<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total current liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">9,471,257<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">9,648,083<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total liabilities<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">9,471,257<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">9,648,083<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Commitments and contingencies<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Stockholders\u02bc equity (deficit):<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Preferred stock, $0.0001 par value; authorized shares \u2014 5,000,000<br \/> \u00a0 as of June 30, 2024 and December 31, 2023; issued and outstanding shares\u00a0\u2014<br \/> \u00a0 zero as of June 30, 2024 and December 31, 2023<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Common stock, $0.0001 par value; authorized shares \u2014 100,000,000 and<br \/> \u00a0 50,000,000 as of June 30, 2024 and December 31, 2023, respectively; issued <br \/> \u00a0 and outstanding shares\u00a0\u2014 734,836 and 278,558 as of June 30, 2024 and <br \/> December 31, 2023, respectively<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">73<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">28<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Additional paid-in capital<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">128,951,361<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">120,859,873<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Accumulated deficit<\/td>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(126,286,476<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(123,439,438<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total stockholders\u02bc equity (deficit)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">2,664,958<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(2,579,537<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total liabilities and stockholders&#8217; equity (deficit)<\/td>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">12,136,215<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">7,068,546<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p align=\"center\"><\/p>\n<p align=\"center\"><\/p>\n<table align=\"center\" style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td colspan=\"9\" style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \"><strong>Evoke Pharma, Inc.<\/strong><br \/><strong>Condensed Statement of Operations<\/strong><br \/><strong>(unaudited)<\/p>\n<p><\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"6\" style=\"border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \"><strong>Three Months Ended June 30,<\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: center ;  vertical-align: middle; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \"><strong>2024<\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \"><strong>2023<\/strong><\/td>\n<td style=\"text-align: center ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:66%; width:66%; min-width:66%;;vertical-align: bottom ; \">Net product sales<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:14%; width:14%; min-width:14%;;border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">2,551,366<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"max-width:14%; width:14%; min-width:14%;;border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">1,131,368<\/td>\n<td style=\"max-width:1%; width:1%; min-width:1%;;padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Operating expenses:<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Cost of goods sold<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">41,478<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">57,357<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Research and development<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u2014<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">92,357<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Selling, general and administrative<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">3,733,450<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">2,766,077<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total operating expenses<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">3,774,928<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">2,915,791<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Loss from operations<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(1,223,562<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(1,784,423<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Other income (expense):<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td colspan=\"2\" style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Interest income<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">81,001<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">41,164<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;   text-align: left;   padding-left: 15.0px; vertical-align: bottom ; \">Interest expense<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(124,657<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(124,658<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Total other expense<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(43,656<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: solid black 1pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(83,494<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Net loss<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(1,267,218<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: solid black 1pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(1,867,917<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Net loss per share of common stock, basic and diluted<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(0.93<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">$<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">(6.71<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">)<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: bottom ; \">Weighted-average shares used to compute basic and diluted <br \/>\u00a0 \u00a0 net loss per share<\/td>\n<td style=\"text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">1,363,525<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<td style=\"border-top: double black 3pt ; border-bottom: double black 3pt ; text-align: right ;  vertical-align: middle; padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">278,558<\/td>\n<td style=\"padding-left: 0 ; padding-right: 0 ; vertical-align: bottom ; \">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDlhYTg5NGYtZTVlZi00MTNkLTg3NzAtMTQ1NjZlZTdmYjljLTEwMzgyNTM=\/tiny\/Evoke-Pharma-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million Achieved record-high prescription fills during Q2 75% year-over-year prescription fill increase; 32% growth compared to Q1 2024 Two abstracts submitted and accepted by the American College of Gastroenterology (ACG) focusing on use of GIMOTI [&#8230;]\n","protected":false},"author":1,"featured_media":58257,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-58256","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results\" \/>\n<meta property=\"og:description\" content=\"GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-13T12:04:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/08\/Evoke-Pharma-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results\",\"datePublished\":\"2024-08-13T12:04:00+00:00\",\"dateModified\":\"2024-08-13T12:04:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/\"},\"wordCount\":2002,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/\",\"name\":\"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-08-13T12:04:00+00:00\",\"dateModified\":\"2024-08-13T12:04:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/","og_locale":"en_US","og_type":"article","og_title":"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results","og_description":"GIMOTI second quarter net product sales grew 47% quarter-over-quarter and 126% year-over-year, indicating an annual run-rate in excess of $10 million","og_url":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-08-13T12:04:00+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/08\/Evoke-Pharma-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results","datePublished":"2024-08-13T12:04:00+00:00","dateModified":"2024-08-13T12:04:00+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/"},"wordCount":2002,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/","url":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/","name":"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-08-13T12:04:00+00:00","dateModified":"2024-08-13T12:04:00+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/evoke-pharma-inc-reports-second-quarter-2024-financial-results\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=58256"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/58256\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/58257"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=58256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=58256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=58256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}